Literature DB >> 842554

Control of breathing during methadone addiction.

T V Santiago, A C Pugliese, N H Edelman.   

Abstract

Chemical control of breathing was studied before and after the administration of the daily dose of methadone in 14 former heroin addicts who were enrolled in a methadone maintenance program and taking 60 to 100 mg/day. Two major groups were identified: group 1 in which subjects (n=6) had taken the drug for less than two months, and group 2 in which the subjects (n=6) had taken the drug from eight to 43 months. Prior to the daily dose of methadone, the levels of arterial carbon dioxide tension were significantly higher and ventilatory response to hypoxia significantly lower in group 1 than in group 2. Ventilatory responses to carbon dioxide (CO2) were also lower in group 1, but the difference was not statistically significant. Following the daily dose of methadone, the subjects in group 1 manifested significant reductions of ventilation and arterial oxygen tension, significant increases in arterial carbon dioxide tension and significant depressions of ventilatory responses to both CO2 and hypoxia in comparison to values before the administration of methadone. In contrast, subjects in group 2 manifested only a significant decrease in ventilatory responsiveness to hypoxia with no change in ventilation, arterial blood gas tensions or ventilatory responsiveness to CO2 following the daily dose. Two intermediate subjects (five and seven months) behaved as long-term subjects with regard to arterial carbon dioxide tension and CO2 responses but as short-term subjects with regard to responsiveness to hypoxia. Thus, during the first two months of methadone maintence, there is continual alveolar hypoventilation due to depression o both central (CO2) and peripheral (hypoxia) chemoreception. After five months, alveolar hypoventilation is abolished as the CO2-sensitive chemoreflex acquires full tolerance to methadone at the maintenance dose level. In contrast, tolerance of the hypoxia-sensitive chemoreflex is developed more slowly and is never complete.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 842554     DOI: 10.1016/0002-9343(77)90831-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  14 in total

1.  Intravenous methadone application as a serious risk factor for an overdose death: methadone-related fatalities in Hamburg from 2007 to 2012.

Authors:  Stefanie Iwersen-Bergmann; Hilke Jungen; Hilke Andresen-Streichert; Alexander Müller; Sally Elakkary; Klaus Püschel; Axel Heinemann
Journal:  Int J Legal Med       Date:  2014-05-25       Impact factor: 2.686

2.  Opioid-associated central sleep apnea: a case series.

Authors:  M A Alattar; S M Scharf
Journal:  Sleep Breath       Date:  2008-09-20       Impact factor: 2.816

3.  [Not Available].

Authors:  J Jage
Journal:  Schmerz       Date:  1989-09       Impact factor: 1.107

4.  Sleep disordered breathing and chronic respiratory failure in patients with chronic pain on long term opioid therapy.

Authors:  Anand R Rose; Peter G Catcheside; R Doug McEvoy; Denzil Paul; Dilip Kapur; Emily Peak; Andrew Vakulin; Nicholas A Antic
Journal:  J Clin Sleep Med       Date:  2014-08-15       Impact factor: 4.062

5.  Methods in the assessment of the control of breathing.

Authors:  K B Sauders
Journal:  Br J Clin Pharmacol       Date:  1980-01       Impact factor: 4.335

6.  Obstructive sleep apnea and chronic opioid use.

Authors:  Christian Guilleminault; Michelle Cao; Herbert J Yue; Pawan Chawla
Journal:  Lung       Date:  2010-07-24       Impact factor: 2.584

Review 7.  Management of dyspnea in patients with chronic obstructive pulmonary disease.

Authors:  Amy P Abernethy; Hope E Uronis; Jane L Wheeler; David C Currow
Journal:  Wien Med Wochenschr       Date:  2009-12

8.  Adaptive pressure support servoventilation: a novel treatment for sleep apnea associated with use of opioids.

Authors:  Shahrokh Javaheri; Athar Malik; Jason Smith; Eugene Chung
Journal:  J Clin Sleep Med       Date:  2008-08-15       Impact factor: 4.062

9.  Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing.

Authors:  James M Walker; Robert J Farney; Steven M Rhondeau; Kathleen M Boyle; Karen Valentine; Tom V Cloward; Kevin C Shilling
Journal:  J Clin Sleep Med       Date:  2007-08-15       Impact factor: 4.062

Review 10.  Palliative management of refractory dyspnea in COPD.

Authors:  Hope E Uronis; David C Currow; Amy P Abernethy
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.